News
Vaccine for Advanced Prostate Cancer Promising
2/2/2010
Renal & Urology News
Researchers reported on phase 2 trial results showing that Prostvac-VF immunotherapy is well tolerated and associated with a 44% reduction in death rate over a three-year period, with a...click here to learn more about this trial.